Previous 10 | Next 10 |
RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pan...
Dr. Michael Pishvaian, Principal Investigator of Phase III TIGeR-PaC Clinical Trial, will Discuss Recent Interim Analysis and its Potential Practice-Changing Impact in Oncology RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage...
Study is Investigating RenovoGem™ as Potential New Option for Pancreatic Cancer Treatment Recent Positive Interim Data Analysis from Study Revealed 60% Survival Benefit and 65% Side Effect Reduction Versus Systemic Chemotherapy RenovoRx, Inc . (“RenovoRx”...
Company to Present Interim Analysis Secondary Endpoint Data Including Progression-free Survival from Phase III TIGeR-PaC Study, a Multi-center Open-label Study Evaluating RenovoGem™ to Treat Locally Advanced Pancreatic Cancer (LAPC) RenovoRx, Inc . (“RenovoRx” o...
RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced that Shaun Bagai, CEO, will present at the 13th Annual LD Micro Invitational, held on June 6-8, 2023 at the Luxe S...
2023-05-15 12:35:10 ET RenovoRx press release ( NASDAQ: RNXT ): Q1 GAAP EPS of -$0.36. Cash and cash equivalents as of March 31, 2023, were $3.7 million. Net loss was $3.3 million for the quarter ended March 31, 2023, compared to net loss of $3.0 million for year ended...
Announced Phase III Interim Study Analysis Results: 60% Survival Benefit and Greater than 65% Reduction in Side Effects with RenovoGem ™ Compared to Systemic Chemotherapy in Pancreatic Cancer RenovoRx, Inc. (“RenovoRx” or the “Company”) (Na...
Researchers Presenting Interim Data on Poster #CT084 Demonstrating RenovoGem™ Patients May Experience 60% Survival Benefit and 65% Side Effects Reduction Versus Systemic Chemotherapy RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopha...
Ms. Gentry, an Industry Expert in Clinical Trials Management, Adds Valuable Leadership Experience to Advance Studies in Cancer Treatment RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatm...
2023-03-30 13:33:41 ET RenovoRx ( NASDAQ: RNXT ) entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1.56M shares at a purchase price of $3.21/share in a registered direct offering. Offering is exp...
News, Short Squeeze, Breakout and More Instantly...
LOS ALTOS, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today annou...
LOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...